SEC Form 4 · accession 0001140361-18-015588
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Mar 26, 2018
Accepted (ET)
Mar 28, 2018 · 6:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 26, 2018 | M | 1,000 | $14.39 | A | 285,031 | D | |
| Common Stock | Mar 27, 2018 | M | 1,000 | $14.39 | A | 286,031 | D | |
| Common Stock | holding | — | — | — | 182,201 | I | Shares held by Jean-Jacques Bienaime Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1 | $14.39 | Mar 26, 2018 | M | 1,000 | A | Nov 12, 2009 | May 11, 2019 | Common Stock | 1,000 | 111,000 | D |
| Stock Option (Right to buy Common Stock)F1 | $14.39 | Mar 27, 2018 | M | 1,000 | A | Nov 12, 2009 | May 11, 2019 | Common Stock | 1,000 | 110,000 | D |
Explanation of responses
- F1Reflects the number of options outstanding after the transactions from this specific stock option grant.